AbbVie

Selected news for the company - AbbVie, collected since 10/2017. This company shares news with Allergan, Pfizer, Amgen, Merck, Novartis and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B FiercePharma Ahead of its state-of-the-company address at the J.P. Morgan Healthcare Conference, AbbVie took the unusual step of reconfirming its guidance for its blockbusters-in-waiting Rinvoq and Skyrizi, saying it expects the duo's sales to reach a combined $15 billion in 2025.Why update an estimate that hasn’t changed?While AbbVie expects the two to produce the same combined revenue, there has been some movement on ...
1/12/2022 AbbVie's guidance for Skyrizi and Rinvoq lifts remaining overhang - Morgan Stanley Seeking Alpha ... 7Cbutton%3Aauthorname%7Cfirstlevel_url%3Anews) , SA News Editor 6 Comments[AbbVie Inc. (ABBV)][By: Dulan Lokuwithana] , SA News Editor[6 Comments]- Morgan Stanley has welcomed the recent sales guidance issued by AbbVie ( [ABBV] -0.4%) for Rinvoq (upadacitinib) and Skyrizi (risankizumab).- In a press release on Tuesday, the North Chicago, Illinois-based biotech reaffirmed its previous revenue guidance of more than $15B risk-adjusted sales [for the treatments ...
1/12/2022 Mizuho Americas Hires Graig C. Suvannavejh, PhD, as Senior Biopharmaceuticals and Biotechnology Analyst | 2022-01-12 | Press Releases | Stockhouse stockhouse.com ... in healthcare which includes research roles at both bulge bracket and healthcare-dedicated boutique investment banks and corporate experience with operating roles in business development and strategy at top-tier global biopharmaceutical companies, including AbbVie and Biogen. He joins Mizuho from Goldman Sachs, where he successfully built out and led the European biotechnology research franchise there, and was a key player in the firm&CloseCurlyQuote: ;s US biopharmaceuticals research efforts ...
1/11/2022 Synlogic (NASDAQ:SYBX) Rating Lowered to Hold at Zacks Investment Research rivertonroll.com ... company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. “Several other equities research analysts have also recently issued reports on ...
1/11/2022 Brokerages Set AbbVie Inc. (NYSE:ABBV) Price Target at $135.15 Dakota Financial News ... target price among brokerages that have issued ratings on the stock in the last year is $135.15.Several research analysts recently issued reports on ABBV shares. Truist upped their target price on shares of AbbVie from $118.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, November 24th. Mizuho upped their target price on shares of AbbVie from $132.00 to $154.00 and gave ...
1/11/2022 AbbVie Inc. (NYSE:ABBV) Receives $135.15 Consensus PT from Brokerages The Markets Daily Shares of AbbVie Inc. (NYSE:ABBV) have received an average rating of “Buy” from the sixteen ratings firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $135.15 ...
1/11/2022 AbbVie Inc. (ABBV) to Issue Quarterly Dividend of $1.41 on February 15th - Dakota Financial News Dakota Financial News ... Tuesday, February 15th. This represents a $5.64 dividend on an annualized basis and a dividend yield of 4.14%. The ex-dividend date of this dividend is Thursday, January 13th. This is a boost from AbbVie ’s previous quarterly dividend of $1.30.AbbVie has raised its dividend by 44.9% over the last three years and has raised its dividend annually for the last 50 consecutive years. AbbVie has a dividend payout ...
1/11/2022 South Dakota Investment Council Has $6.91 Million Position in AbbVie Inc. (NYSE:ABBV) - The Cerbat Gem thecerbatgem.com South Dakota Investment Council lowered its position in AbbVie Inc. (NYSE:ABBV) by 32.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 64,057 shares of the company’s stock after selling 31,066 shares during the period. South Dakota Investment Council’s holdings in AbbVie were worth $6,910,000 at the end of the most recent reporting period.A number of other ...
1/11/2022 AbbVie Inc. (NYSE:ABBV) Shares Bought by CIBC Asset Management Inc - Ticker Report Ticker Report CIBC Asset Management Inc raised its position in AbbVie Inc. (NYSE:ABBV) by 1.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 210,503 shares of the company’s stock after acquiring an additional 3,612 shares during the period. CIBC Asset Management Inc’s holdings in AbbVie were worth $22,704,000 at the end of the most recent reporting period.Several other hedge funds ...
1/11/2022 AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq Skyrizi in 2025 PR Newswire NORTH CHICAGO, Ill. , Jan. 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV ) is confirming prior revenue guidance of greater than $15 billion in combined Rinvoq (upadacitinib) and Skyrizi (risankizumab) risk-adjusted sales in 2025. AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi. The new Rinvoq sales guidance is the result of lower expected Rinvoq sales in the U.S. following ...
1/11/2022 South Dakota Investment Council Sells 31,066 Shares of AbbVie Inc. (NYSE:ABBV) baseballnewssource.com South Dakota Investment Council decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 32.7% in the third quarter, HoldingsChannel reports. The firm owned 64,057 shares of the company’s stock after selling 31,066 shares during the quarter. South Dakota Investment Council’s holdings in AbbVie were worth $6,910,000 at the end of the most recent quarter.A number of other institutional investors and hedge funds have also added ...
1/11/2022 AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025 Yahoo News NORTH CHICAGO, Ill. , Jan. 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) is confirming prior revenue guidance of greater than $15 billion in combined Rinvoq (upadacitinib) and Skyrizi (risankizumab) risk-adjusted sales in 2025. AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi. The new Rinvoq sales guidance is the result of lower expected Rinvoq sales in the U.S. following ...
1/11/2022 AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025 PR Newswire NORTH CHICAGO, Ill. AbbVie (NYSE: ABBV ) is confirming prior revenue guidance of greater than $15 billion in combined Rinvoq (upadacitinib) and Skyrizi (risankizumab) risk-adjusted sales in 2025. AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi. The new Rinvoq sales guidance is the result of lower expected Rinvoq sales in the U.S. following the recent label updates ...
1/11/2022 Catalyst Capital Advisors LLC Cuts Stock Holdings in AbbVie Inc. (NYSE:ABBV) - Stock Observer thestockobserver.com Catalyst Capital Advisors LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 96.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,290 shares of the company’s stock after selling 36,600 shares during the quarter. Catalyst Capital Advisors LLC’s holdings in AbbVie were worth $139,000 as of its most recent filing with the Securities ...
1/11/2022 Gulf International Bank UK Ltd Has $37.65 Million Stake in AbbVie Inc. (NYSE:ABBV) Daily Political Gulf International Bank UK Ltd reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 349,048 shares of the company’s stock after selling 3,793 shares during the quarter. Gulf International Bank UK Ltd’s holdings in AbbVie were worth $37,651,000 as of its most recent filing with the SEC. Several ...
1/11/2022 AlivaMab Discovery Services Appoints Jane Seagal, PhD, as Vice President of Antibody Discovery | Business Wire Business Wire ... Science, in leading therapeutic antibody discovery programs for a rapidly expanding list of partners, which includes IGM Biosciences, Janssen, Tanabe Research Labs, Teva Pharmaceuticals and dozens of other companies.Dr. Seagal joins ADS from AbbVie where, as Research Fellow, Drug Discovery Science and Technology, she headed the in vivo antibody discovery group, led projects across diverse therapeutic areas including oncology, immunology and virology, and chaired a cross-functional team of ...
1/11/2022 JLB & Associates Inc. Sells 1,200 Shares of AbbVie Inc. (NYSE:ABBV) - WKRB News wkrb13.com JLB & Associates Inc. cut its stake in AbbVie Inc. (NYSE:ABBV) by 2.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,403 shares of the company’s stock after selling 1,200 shares during the quarter. JLB & Associates Inc.’s holdings in AbbVie were worth $5,652,000 as of its most recent SEC filing.Other institutional investors and ...
1/11/2022 AbbVie Inc. (NYSE:ABBV) Position Lowered by Westchester Capital Management Inc. Dakota Financial News Westchester Capital Management Inc. decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 0.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 114,358 shares of the company’s stock after selling 385 shares during the period. AbbVie comprises about 3.4% of Westchester Capital Management Inc.’s investment portfolio, making the stock its 16th biggest holding. Westchester Capital Management ...
1/11/2022 ACELYRIN Appoints Melanie Gloria as Chief Operating Officer stockhouse.com ... variety of research and development (R&D) functions. She is an experienced people leader who has managed large, diverse teams that achieved global approvals for blockbuster and life-saving therapies at Abbott (NYSE:ABT), AbbVie (NYSE: ABBV), and Horizon Therapeutics (NASDAQ: HZNP). Before joining ACELYRIN, she was senior vice president of development operations at Horizon."On behalf of the entire ACELYRIN leadership team, I am delighted to welcome Melanie as ...
1/11/2022 AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025 stockhouse.com ABBV 2 hours ago NORTH CHICAGO, Ill. , Jan. 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) is confirming prior revenue guidance of greater than $15 billion in combined Rinvoq (upadacitinib) and Skyrizi (risankizumab) risk-adjusted sales in 2025. AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi. The new Rinvoq sales guidance is the result of lower expected Rinvoq sales ...